Study 304, Study 306, and the FDA Path: What’s Next for VDPHL01
The April 27, 2026 announcement from Veradermics confirmed what investors and hair loss patients had been waiting months to hear: […]
News
News
VDPHL01 Phase 2/3 Trial Results: Early, Robust Hair Growth — and a Clean Safety Record
On April 27, 2026, Veradermics (NYSE: MANE) released positive topline data from Study ‘302’ — the first of two pivotal